FATE News and Press, Fate Therapeutics Inc.

A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...

2024-06-17 07:30:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for FATE on June 17, 2024 06:03AM ET. The previous analyst recommendation was Neutral. FATE was trading at $3.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-05-31 18:09:07 ET More on Fate Therapeutics Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom Fate Therapeutics: Looking For A Potential Turnaround In 2024 Fate Therapeutics...

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellula...

2024-05-11 18:12:07 ET Fate Therapeutics, Inc. (FATE) Q1 2024 Results Conference Call May 09, 2024 05:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Bob Valamehr - Chief Research and Development Officer Conference Call Partic...

2024-05-09 16:04:34 ET More on Fate Therapeutics Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom Fate Therapeutics: Looking For A Potential Turnaround In 2024 Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript Fate Therapeutics...

First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 ...

Pre-treatment Sample of Patient’s Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819 Translational Data from FT819 Phase 1 B Cell Malignancies Study Support Key Therapeutic Mechanisms of Activity for B Cell-mediated Autoimmune Diseas...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-05-08 17:35:57 ET More on Fate Therapeutics Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom Fate Therapeutics: Looking For A Potential Turnaround In 2024 Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript Fate Therapeutics...